IDH1 and central nervous system cancer: Patients with IDH1/2 mutated 1p19q codeleted gliomas had longer median OS (cyan, 168.2 months; 95% CI: 153.0–NA) than those with IDH1/2 mutations without 1p19q codeletion (navy blue, 121.6 months; 95% CI: 107.0–225.0; HR: 0.42; 95% CI: 0.20–0.90; P < .05, Figure 5C).